Analytical Data
-
基因名
IL-28R beta
- Application
-
别名
Fibronectin type III domain containing 6 (FNDC6) (IL-20 receptor subunit beta) (IL-20R-beta) (IL-20RB) (IL-20R2) (DIRS1)
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 85% as determined by SDS-PAGE. as determined by SDS-PAGE.
-
蛋白编号
Q6UXL0
-
表达区间
30-233aa
-
分子量
26.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-28R beta, or interleukin-28 receptor beta, is a crucial component of the type III interferon receptor complex, which plays a significant role in the immune response against viral infections. Researchers have been increasingly focused on IL-28R beta due to its involvement in regulating antiviral activity, particularly in the context of hepatitis C virus (HCV) infections. The receptor facilitates cellular responses to interferon lambda (IFN-λ), a type of interferon that exhibits potent antiviral properties with fewer side effects compared to traditional interferons. Understanding the structure and function of IL-28R beta is essential for exploring therapeutic strategies that leverage the immune system, particularly for patients who may not respond well to other forms of antiviral treatment. Experimental approaches, including the production of recombinant IL-28R beta proteins, aim to clarify its signaling mechanisms and interactions with IFN-λ. This research could lead to the development of novel immunotherapies that enhance the body’s antiviral defenses while minimizing adverse reactions. With the rising concerns around antiviral drug resistance and the increasing incidence of chronic viral infections worldwide, deciphering the role of IL-28R beta in immune modulation presents promising avenues for improved clinical outcomes in the management of viral diseases.
